BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

855 related articles for article (PubMed ID: 26494232)

  • 1. Cell-Free DNA Modulates Clot Structure and Impairs Fibrinolysis in Sepsis.
    Gould TJ; Vu TT; Stafford AR; Dwivedi DJ; Kim PY; Fox-Robichaud AE; Weitz JI; Liaw PC
    Arterioscler Thromb Vasc Biol; 2015 Dec; 35(12):2544-53. PubMed ID: 26494232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA, histones and neutrophil extracellular traps exert anti-fibrinolytic effects in a plasma environment.
    Varjú I; Longstaff C; Szabó L; Farkas ÁZ; Varga-Szabó VJ; Tanka-Salamon A; Machovich R; Kolev K
    Thromb Haemost; 2015 Jun; 113(6):1289-98. PubMed ID: 25789443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zinc delays clot lysis by attenuating plasminogen activation and plasmin-mediated fibrin degradation.
    Henderson SJ; Stafford AR; Leslie BA; Kim PY; Vaezzadeh N; Ni R; Fredenburgh JC; Weitz JI
    Thromb Haemost; 2015 Jun; 113(6):1278-88. PubMed ID: 25789495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA-bound elastase of neutrophil extracellular traps degrades plasminogen, reduces plasmin formation, and decreases fibrinolysis: proof of concept in septic shock plasma.
    Cruz DBD; Helms J; Aquino LR; Stiel L; Cougourdan L; Broussard C; Chafey P; Riès-Kautt M; Meziani F; Toti F; Gaussem P; Anglés-Cano E
    FASEB J; 2019 Dec; 33(12):14270-14280. PubMed ID: 31682515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibrin clot structure - pro-fibrinolytic effect of oral contraceptives in apparently healthy women.
    Sidelmann JJ; Kluft C; Krug AH; Winkler U; Jespersen J; Gram JB
    Thromb Haemost; 2017 Apr; 117(4):700-705. PubMed ID: 28150855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of plasmin generation and clot lysis of plasma fibrinogen purified from a heterozygous dysfibrinogenemia, BbetaGly15Cys (Hamamatsu II).
    Kamijyo Y; Hirota-Kawadobora M; Yamauchi K; Terasawa F; Honda T; Ikeya M; Okumura N
    Blood Coagul Fibrinolysis; 2009 Dec; 20(8):726-32. PubMed ID: 19809304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced plasminogen binding and delayed activation render γ'-fibrin more resistant to lysis than γA-fibrin.
    Kim PY; Vu TT; Leslie BA; Stafford AR; Fredenburgh JC; Weitz JI
    J Biol Chem; 2014 Oct; 289(40):27494-503. PubMed ID: 25128532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased plasma clot permeability and susceptibility to lysis are associated with heavy menstrual bleeding of unknown cause: a case-control study.
    Szczepaniak P; Zabczyk M; Undas A
    PLoS One; 2015; 10(4):e0125069. PubMed ID: 25909989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of the fibrinolytic system and utilization of the coagulation inhibitors in sepsis: comparison with severe sepsis and septic shock.
    Mavrommatis AC; Theodoridis T; Economou M; Kotanidou A; El Ali M; Christopoulou-Kokkinou V; Zakynthinos SG
    Intensive Care Med; 2001 Dec; 27(12):1853-9. PubMed ID: 11797019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolonged duration of type 2 diabetes is associated with increased thrombin generation, prothrombotic fibrin clot phenotype and impaired fibrinolysis.
    Konieczynska M; Fil K; Bazanek M; Undas A
    Thromb Haemost; 2014 Apr; 111(4):685-93. PubMed ID: 24306139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of activated coagulation factor XII in overall clot stability and fibrinolysis.
    Konings J; Hoving LR; Ariëns RS; Hethershaw EL; Ninivaggi M; Hardy LJ; de Laat B; Ten Cate H; Philippou H; Govers-Riemslag JW
    Thromb Res; 2015 Aug; 136(2):474-80. PubMed ID: 26153047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cleavage of surfactant-incorporating fibrin by different fibrinolytic agents. Kinetics of lysis and rescue of surface activity.
    Günther A; Markart P; Kalinowski M; Ruppert C; Grimminger F; Seeger W
    Am J Respir Cell Mol Biol; 1999 Dec; 21(6):738-45. PubMed ID: 10572071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble fibrin degradation products potentiate tissue plasminogen activator-induced fibrinogen proteolysis.
    Weitz JI; Leslie B; Ginsberg J
    J Clin Invest; 1991 Mar; 87(3):1082-90. PubMed ID: 1900308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of fibrinolytic activity by measuring the lysis time of a tissue-factor-induced clot: a feasibility evaluation.
    Cellai AP; Lami D; Magi A; Liotta AA; Rogolino A; Antonucci E; Bandinelli B; Abbate R; Prisco D
    Clin Appl Thromb Hemost; 2010 Jun; 16(3):337-44. PubMed ID: 19117964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unfavorably altered fibrin clot properties in patients with active rheumatoid arthritis.
    Kwasny-Krochin B; Gluszko P; Undas A
    Thromb Res; 2010 Jul; 126(1):e11-6. PubMed ID: 20471669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coagulofibrinolytic changes in patients with disseminated intravascular coagulation associated with post-cardiac arrest syndrome--fibrinolytic shutdown and insufficient activation of fibrinolysis lead to organ dysfunction.
    Wada T; Gando S; Mizugaki A; Yanagida Y; Jesmin S; Yokota H; Ieko M
    Thromb Res; 2013 Jul; 132(1):e64-9. PubMed ID: 23726093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct microscopic monitoring of initial and dynamic clot lysis using plasmin or rt-PA in an in vitro flow system.
    Bizjak N; Bajd F; Vidmar J; Blinc A; Perme MP; Marder VJ; Novokhatny V; Serša I
    Thromb Res; 2014 May; 133(5):908-13. PubMed ID: 24613694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modification of fibrinogen by homocysteine thiolactone increases resistance to fibrinolysis: a potential mechanism of the thrombotic tendency in hyperhomocysteinemia.
    Sauls DL; Lockhart E; Warren ME; Lenkowski A; Wilhelm SE; Hoffman M
    Biochemistry; 2006 Feb; 45(8):2480-7. PubMed ID: 16489740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A direct oral anticoagulant edoxaban accelerated fibrinolysis via enhancement of plasmin generation in human plasma: dependent on thrombin-activatable fibrinolysis inhibitor.
    Morishima Y; Honda Y
    J Thromb Thrombolysis; 2019 Jul; 48(1):103-110. PubMed ID: 30972711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An analysis of mechanisms underlying the antifibrinolytic properties of radiographic contrast agents.
    Farrehi PM; Zhu Y; Fay WP
    J Thromb Thrombolysis; 2001 Dec; 12(3):273-81. PubMed ID: 11981110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.